Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis

Annals of the New York Academy of Sciences

Volumn 1050, Issue , 2005, Pages 185-192

  Sinico, Renato Alberto ^a   Radice, Antonella ^a   Corace, Caterina ^a   Di Toma, Lucafrancesco ^a   Sabadini, Ettore ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

ANCA associated systemic vasculitis; Anti neutrophil cytoplasmic antibodies (ANCAs); Birmingham Vasculitis Activity Score (BVAS); Churg Strauss syndrome; Disease activity; Microscopic poly angiitis; Wegener's granulomatosis

Indexed keywords

MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEROXIDASE; PEROXIDASE 3; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ANTIBODY TITER; AUTOANALYSIS; BIRMINGHAM VASCULITIS ACTIVITY SCORE; BLOOD SAMPLING; CHURG STRAUSS SYNDROME; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME FLUOROIMMUNOASSAY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MICROSCOPIC POLYANGIITIS; MONITORING; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 23744442068     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1313.019     Document Type: Conference Paper

References (31)

1. WIIK, A. 1989. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl. 6: 12-13.
2. DAVIES, D.J., J.E. MORAN, J.F. NIALL & G.B. RYAN. 1982. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J. (Clin. Res. Ed.) 285: 606.
3. VAN DER WOUDE, F.J., N. RASMUSSEN, S. LOBATTO, et al. 1985. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegeners granulomatosis. Lancet 1: 425-429.
4. FALK, R.J. & I.C. JENNETTE. 1988. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N. Engl. J. Med. 318: 1651-1657.
5. GOLDSCHMEDING, R., C.E. VAN DER SCHOOT, D. TEN BOKKEL HUININK, et al. 1989. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J. Clin. Invest. 84: 1577-1587.
6. CAMBRIDGE, G., D.S. RAMPTON, T.R. STEVENS, et al. 1992. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 33: 668-674.
7. VECCHI, M., M.B. BIANCHI, R.A. SINICO, et al. 1994. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion. 55: 34-39.
8. MULDER, A.H., G. HORST, E.B. HAAGSMA, et al. 1993. Prevalence and characterization of anti-neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 17:411-417.
9. COREMANS, I.E., E.G. HAGEN, M.R. DAHA, et al. 1992. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum. 35: 1466-1475.
10. GROSS, W.L., W.H. SCHMITT & E. CSERNOK. 1993. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin. Exp. Immunol. 91: 1-12.
11. PEEN, E., S. ALMER, G. BODEMAR, et al. 1993. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 34: 56-62.
12. HALBWACHS-MECARELLI, L., P. NUSBAUM, L.H. NOEL, et al. 1992. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin. Exp. Immunol. 90: 79-84.
13. KANEKO, K., Y. SUZUKI, Y. YAMASHIRO & K. YABUTA. 1993. Is p-ANCA in ulcerative colitis directed against β-glucuronidase? Lancet. 341: 320.
14. VECCHI, M., A. SINICO, M.B. BIANCHI, et al. 1998. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance. Scand. J. Gastroenterol. 33: 1284-1288.
15. SINICO, R.A., C. POZZI, A. RADICE, et al. 1993. Clinical significance of antineutrophil cytoplasmic autoantibodies with specificity for lactoferrin in renal diseases. Am. J. Kidney Dis. 22: 253-260.
16. MERKEL, P.A., R.P. POLISSON, Y. CHANG, et al. 1997. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann. Int. Med. 126: 866-873.
17. SINICO, R.A., A. RADICE, C. POZZI, et al. 1994. Diagnostic significance and antigen specificity of antineutrophil cytoplasmic antibodies in renal disease: a prospective multicentre study. Nephrol. Dial. Transplant. 9: 505-510.
18. HAGEN, E.C., M.R. DAHA, J. HERMANS, et al. 1998. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 53: 743-753.
19. RAO, J.K., M. WEINBERGER, E.Z. ODDONE, et al. 1995. The role of antineutrophil cytoplasmic antibody (C-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. Ann. Intern. Med. 123: 925-932.
20. JENNETTE, J.C., A.S. WILKMAN & R.J. FALK. 1998. Diagnostic predictive value of ANCA serology. Kidney Int. 53: 796-798.
21. CHOI, H.K., S. LIU, P.A. MERKEL, et al. 2001. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with focus on antimyeloperoxidase antibodies. J. Rheumatol. 28: 1584-1590.
22. BOOMSMA, M.M., C.A. STEGEMAN, M.J. VAN DER LEIJ, et al. 2000. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 43: 2025-2033.
23. KERR, G.S., T.A. FLEISHER, C.W. HALLAHAN, et al. 1993. Limited prognostic value of changes in antineutrophil cytoplasm antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 36: 365-371.
24. GIRARD, T., A. MAHR, L.H. NOEL, et al. 2001. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology 40: 147-151.
25. HAN, W.K., H.K. CHOI, R.M. ROTH, et al. 2003. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int. 63: 1079-1085.
26. JENNETTE, J.C., R.J. FALK, et al. 1994. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 37: 187-192.
27. MASI, A.T., G.G. HUNDER, J.T. LIE, et al. 1990. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 33: 1094-1100.
28. LUQMANI, R.A., P.A. BACON, R.J. MOOTS, et al. 1994. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q.J.M. 87: 671-678.
29. RADICE, A., M. VECCHI, M.B. BIANCHI & R.A. SINICO. 2000. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies: the role of different fixatives. Clin. Exp. Rheumatol. 18: 707-712.
30. SAVIGE, J., D. DAVIES, R.J. FALK, et al. 2000. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int. 57: 846-862.
31. SAVIGE, J., W. DIMECH, M. FRITZLER, et al. for the International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). 2003. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies: quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am. J. Clin. Pathol. 120: 312-318.